Loading
Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.
Clifutinib (HEC73543) is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05586074 (HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML), in acute myeloid leukaemia. The largest, NCT05586074, plans to enrol 324 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Clifutinib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Clifutinib" OR ABSTRACT:"Clifutinib" OR TITLE:"HEC73543" OR ABSTRACT:"HEC73543") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Clifutinib, not a curated reading list.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.